Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak

Frenois-Veyrat, Gaëlle; Gallardo, Franck; Gorgé, Olivier; Marcheteau, Elie; Ferraris, Olivier; Baidaliuk, Artem; Favier, Anne-Laure; Enfroy, Cécile; Holy, Xavier; Lourenco, Jérémy; Khoury, Rhéa; Nolent, Flora; Grosenbach, Douglas W.; Hruby, Dennis E.; Ferrier, Audrey; Iseni, Frédéric; Simon‐Lorière, Etienne; Tournier, Jean‐Nicolas

doi:10.1101/2022.07.19.500484

Cited by 13 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…309,[313][314][315][316][317] Tecovirimat has a distinguished antiviral effect against the monkeypox virus lineage responsible for the 2022 outbreak in vitro. 318 Further, the effectiveness and safety of tecovirimat has been revealed in multiple animal studies. [319][320][321][322][323][324] Treatment with 10 mg per kilogram of body weight of tecovirimat for 14 days in the monkeypox model could achieve >90% survival.…”

Section: Treatmentmentioning

confidence: 99%

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Huang

Wang

2022

Sig Transduct Target Ther

165

120

View full text Add to dashboard Cite

Monkeypox is a zoonotic disease that was once endemic in west and central Africa caused by monkeypox virus. However, cases recently have been confirmed in many nonendemic countries outside of Africa. WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on July 23, 2022, in the context of the COVID-19 pandemic. The rapidly increasing number of confirmed cases could pose a threat to the international community. Here, we review the epidemiology of monkeypox, monkeypox virus reservoirs, novel transmission patterns, mutations and mechanisms of viral infection, clinical characteristics, laboratory diagnosis and treatment measures. In addition, strategies for the prevention, such as vaccination of smallpox vaccine, is also included. Current epidemiological data indicate that high frequency of human-to-human transmission could lead to further outbreaks, especially among men who have sex with men. The development of antiviral drugs and vaccines against monkeypox virus is urgently needed, despite some therapeutic effects of currently used drugs in the clinic. We provide useful information to improve the understanding of monkeypox virus and give guidance for the government and relative agency to prevent and control the further spread of monkeypox virus.

show abstract

Section: Treatmentmentioning

confidence: 99%

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Huang

Wang

2022

Sig Transduct Target Ther

165

120

View full text Add to dashboard Cite

show abstract

“…All members of the Orthopoxvirus genus share the viral F13 target, which provides a rationale for utilizing surrogate orthopoxviruses to test the effectiveness of tecovirimat 76 . Recent research revealed that Tecovirimat is very effective against the MPXV lineage that caused the global 2022 outbreak 120 …”

Section: Monkeypox Therapeutic Drug Targets and Strategiesmentioning

confidence: 99%

Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies

Rabaan

Abas

Tallei

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Monkeypox is a rare zoonotic disease caused by infection with the monkeypox virus. The disease can result in flu‐like symptoms, fever, and a persistent rash. The disease is currently spreading throughout the world and prevention and treatment efforts are being intensified. Although there is no treatment that has been specifically approved for monkeypox virus infection, infected patients may benefit from using certain antiviral medications that are typically prescribed for the treatment of smallpox. The drugs are tecovirimat, brincidofovir, and cidofovir, all of which are currently in short supply due to the spread of the monkeypox virus. Resistance is also a concern, as widespread replication of the monkeypox virus can lead to mutations that produce monkeypox viruses that are resistant to the currently available treatments. This article discusses monkeypox disease, potential drug targets, and management strategies to overcome monkeypox disease. With the discovery of new drugs, it is hoped that the problem of insufficient drugs will be resolved, and it is not anticipated that drug resistance will become a major issue in the near future.

show abstract

“…Monkeypox is caused by Monkeypox virus (MPXV), a member of the Orthopoxvirus genus of the Poxviridae family and results in pox-like skin lesions, making the diagnosis difficult with chickenpox virus infection. , MPXV is endemic in a dozen countries in West and Central Africa . The 2022 outbreak virus belongs to MPXV clade 3 (within the formerly designated “West African” clade, which also includes clade 2). − MPXV belonging to clade 1 (formerly designated “Congo Basin” clade) is associated with more severe disease compared to clades 2 and 3. ,,, This Monkeypox outbreak was reported on May 7, 2022, in the United Kingdom . Since June 27, 2022, Monkeypox cases have been reported to the World Health Organization (WHO) in 43 member states for which Monkeypox was not endemic .…”

Section: Introductionmentioning

confidence: 99%

First Detection of Monkeypox Virus Genome in Sewersheds in France: The Potential of Wastewater-Based Epidemiology for Monitoring Emerging Disease

Wurtzer

Levert

Dhenain

et al. 2022

Environ. Sci. Technol. Lett.

Self Cite

View full text Add to dashboard Cite

A monkeypox virus outbreak has been spreading in multiple nonendemic countries since May 2022. The atypical clinical profile of patients has led to a very likely underestimation of the number of cases at the beginning of the epidemic. The detection and quantification of the Monkeypox virus genome in sewersheds in Paris (France) correlated temporally with the identification of the first case of infection and the spread of the disease within the population connected to the sewage system.

show abstract

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak

Cited by 13 publications

References 26 publications

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies

First Detection of Monkeypox Virus Genome in Sewersheds in France: The Potential of Wastewater-Based Epidemiology for Monitoring Emerging Disease

Contact Info

Product

Resources

About